Janney Montgomery Scott LLC Sells 6,603 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Janney Montgomery Scott LLC cut its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 9.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 66,126 shares of the biotechnology company’s stock after selling 6,603 shares during the quarter. Janney Montgomery Scott LLC’s holdings in ADMA Biologics were worth $1,134,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hollencrest Capital Management bought a new position in ADMA Biologics during the third quarter worth $30,000. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at about $31,000. GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the period. National Bank of Canada FI bought a new stake in ADMA Biologics in the 3rd quarter valued at about $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics during the 3rd quarter worth approximately $62,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Up 2.6 %

ADMA stock opened at $16.90 on Wednesday. The firm has a market capitalization of $3.99 billion, a PE ratio of 60.36 and a beta of 0.75. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.02 and a twelve month high of $23.64. The stock’s 50 day moving average is $17.90 and its 200-day moving average is $17.66.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the firm earned $0.01 EPS. Sell-side analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ADMA. HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

Insider Buying and Selling at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.